However, dorzagliatin’s mechanism of action, which enhances glucose-stimulated insulin secretion and GLP-1 release while improving β-cell function and reducing insulin resistance in type 2 diabetes patients, may mitigate the risk of severe hypoglycemia. This evidence concerns the gene INS and Insulin resistance.